bioRxiv Science⌕ Search

Biology subjects

Busby, T.

Publications and source records attributed to Busby, T..

2 recordsLinked to original sources

Re-establishment of TAD boundary organization during DNA replication

A ubiquitous feature of higher order genome organization is the presence of topologically associating domains (TADs). The chromatin architectural proteins cohesin and CTCF are known critical organizers of TADs, but the mechanisms of TAD establishment and maintenance, including their accurate duplication during genome replication, are not well characterized. To address this gap, we used high-throughput imaging-based CRISPR/Cas9 knock-out screening to discover chromatin factors involved in maintenance and establishment of TADs. Among the cellular factors that affect TAD organization, we found enrichment for cell cycle proteins, especially components of the DNA replication machinery. Accordingly, we demonstrate that TADs undergo temporary unfolding during S-phase DNA replication and that interference with progression through replication impedes restoration of normal TAD structure. Mechanistically, inhibition of the RPA complex prevents cohesin and CTCF binding, delays post-replication TAD re-folding and affects TAD folding in non-cycling cells. These results provide novel insights into how TAD structures are re-established during genome duplication.

cell biology↗

Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth

DPY30 facilitates H3K4 methylation by directly binding to ASH2L in the SET1/MLL complexes and plays an important role in hematologic malignancies. However, the domain on DPY30 that regulates cancer growth is not evident, and the potential of pharmacologically targeting this chromatin modulator to inhibit cancer has not been explored. Here we have developed a peptide-based strategy to specifically target DPY30 activity. We have designed cell-penetrating peptides derived from ASH2L that can either bind to DPY30 or show defective or enhanced binding to DPY30. The DPY30-binding peptides specifically inhibit its activity in interacting with ASH2L and enhancing H3K4 methylation. Treatment with the DPY30-binding peptides significantly inhibited the growth of MLL-rearranged leukemia and other MYC-dependent hematologic cancer cells. We also revealed subsets of genes that may mediate the effect of the peptides on cancer cell growth, and showed that the DPY30-binding peptide sensitized leukemia to other types of epigenetic inhibitors. These results strongly support a critical role of the ASH2L-binding groove of DPY30 in promoting blood cancers, and demonstrate a proof-of-principle for the feasibility of pharmacologically targeting the ASH2L-binding groove of DPY30 for potential cancer inhibition.

cancer biology↗